{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:17:30Z","timestamp":1791580650911,"version":"4.3.4"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/nrclinonc.2017.197","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T08:17:44Z","timestamp":1515485864000},"page":"219-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["The bone-marrow niche in MDS and MGUS: implications for AML and MM"],"prefix":"10.1038","volume":"15","author":[{"given":"Irene M.","family":"Ghobrial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Detappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"BFnrclinonc2017197_CR1","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2010.28.3978","volume":"29","author":"J Schanz","year":"2011","unstructured":"Schanz, J. et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J. Clin. Oncol. 29, 1963\u20131970 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR2","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616\u20133627 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR3","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454\u20132465 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9\u201316 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR5","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2141.1998.01114.x","volume":"103","author":"JE Parker","year":"1998","unstructured":"Parker, J. E. et al. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br. J. Haematol. 103, 1075\u20131082 (1998).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.leukres.2010.05.023","volume":"34","author":"M Mittelman","year":"2010","unstructured":"Mittelman, M., Oster, H. S., Hoffman, M. & Neumann, D. The lower risk MDS patient at risk of rapid progression. Leuk. Res. 34, 1551\u20131555 (2010).","journal-title":"Leuk. Res."},{"key":"BFnrclinonc2017197_CR8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090\u20131098 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR9","doi-asserted-by":"crossref","unstructured":"Enrico, A. et al. Influence of acute myeloid leukemia progression on the prognosis of 831 patients with myelodysplastic syndromes from the Argentine database. Clin. Lymphoma Myeloma Leuk. 743\u2013752.e5 (2017).","DOI":"10.1016\/j.clml.2017.06.024"},{"key":"BFnrclinonc2017197_CR10","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS \u00d8stg\u00e5rd","year":"2015","unstructured":"\u00d8stg\u00e5rd, L. S. et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J. Clin. Oncol. 33, 3641\u20133649 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley, R. C. et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125, 1367\u20131376 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR12","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR13","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418\u20135422 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","volume":"2013","author":"O Landgren","year":"2013","unstructured":"Landgren, O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematol. Am. Soc. Hematol. Educ. Program 2013, 478\u2013487 (2013).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"BFnrclinonc2017197_CR15","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","volume":"86","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86, 57\u201365 (2011).","journal-title":"Am. J. Hematol."},{"key":"BFnrclinonc2017197_CR17","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","volume":"26","author":"L Lopez-Corral","year":"2012","unstructured":"Lopez-Corral, L. et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia 26, 2521\u20132529 (2012).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.leukres.2015.06.017","volume":"39","author":"CR Cogle","year":"2015","unstructured":"Cogle, C. R. et al. Bone marrow niche in the myelodysplastic syndromes. Leuk. Res. 39, 1020\u20131027 (2015).","journal-title":"Leuk. Res."},{"key":"BFnrclinonc2017197_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/leu.2014.325","volume":"29","author":"E Bulycheva","year":"2015","unstructured":"Bulycheva, E. et al. Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia 29, 259\u2013268 (2015).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR20","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2015-07-533588","volume":"126","author":"LM Calvi","year":"2015","unstructured":"Calvi, L. M. & Link, D. C. The hematopoietic stem cell niche in homeostasis and disease. Blood 126, 2443\u20132451 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR21","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/1381612822666160226132914","volume":"22","author":"A Mies","year":"2016","unstructured":"Mies, A., Bulycheva, E., Rogulj, I. M., Hofbauer, L. C. & Platzbecker, U. Alterations within the osteo-hematopoietic niche in MDS and their therapeutic implications. Curr. Pharm. Des. 22, 2323\u20132332 (2016).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrclinonc2017197_CR22","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.4081\/hr.2010.e4","volume":"2","author":"A Raza","year":"2010","unstructured":"Raza, A., Cruz, R., Latif, T., Mukherjee, S. & Galili, N. The biology of myelodysplastic syndromes: unity despite heterogeneity. Hematol. Rep. 2, e4 (2010).","journal-title":"Hematol. Rep."},{"key":"BFnrclinonc2017197_CR23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542\u20131555 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc2017197_CR24","first-page":"26","volume":"1846","author":"M Moschetta","year":"2014","unstructured":"Moschetta, M. et al. Role of endothelial progenitor cells in cancer progression. Biochim. Biophys. Acta 1846, 26\u201339 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrclinonc2017197_CR25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1541-7786.MCR-14-0150","volume":"13","author":"B Muz","year":"2015","unstructured":"Muz, B., de la Puente, P., Azab, F., Ghobrial, I. M. & Azab, A. K. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenstrom's macroglobulinemia. Mol. Cancer Res. 13, 263\u2013272 (2015).","journal-title":"Mol. Cancer Res."},{"key":"BFnrclinonc2017197_CR26","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","volume":"124","author":"MR Reagan","year":"2014","unstructured":"Reagan, M. R. et al. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood 124, 3250\u20133259 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","volume":"9","author":"AM Roccaro","year":"2014","unstructured":"Roccaro, A. M. et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 9, 118\u2013128 (2014).","journal-title":"Cell Rep."},{"key":"BFnrclinonc2017197_CR28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cyto.2014.05.017","volume":"69","author":"A Zingone","year":"2014","unstructured":"Zingone, A. et al. Altered cytokine and chemokine profiles in multiple myeloma and precursor disease. Cytokine 69, 294\u2013297 (2014).","journal-title":"Cytokine"},{"key":"BFnrclinonc2017197_CR29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160\u2013172 (2015).","journal-title":"Immunol. Rev."},{"key":"BFnrclinonc2017197_CR30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","volume":"12","author":"AM Roccaro","year":"2015","unstructured":"Roccaro, A. M. et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 12, 622\u2013635 (2015).","journal-title":"Cell Rep."},{"key":"BFnrclinonc2017197_CR31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2016.3","volume":"30","author":"M Moschetta","year":"2016","unstructured":"Moschetta, M. et al. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia 30, 1103\u20131115 (2016).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-15-1926","volume":"76","author":"A Sacco","year":"2016","unstructured":"Sacco, A. et al. Cancer cell dissemination and homing to the bone marrow in a zebrafish model. Cancer Res. 76, 463\u2013471 (2016).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2017197_CR33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1568009617666170214102301","volume":"17","author":"Y Kawano","year":"2017","unstructured":"Kawano, Y., Roccaro, A. M., Azzi, J. & Ghobrial, I. M. Multiple myeloma and the immune microenvironment. Curr. Cancer Drug Targets 17, 806\u2013818 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"key":"BFnrclinonc2017197_CR34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","volume":"22","author":"R Das","year":"2016","unstructured":"Das, R. et al. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat. Med. 22, 1351\u20131357 (2016).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2017197_CR35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","volume":"16","author":"K Schepers","year":"2015","unstructured":"Schepers, K., Campbell, T. B. & Passegue, E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell 16, 254\u2013267 (2015).","journal-title":"Cell Stem Cell"},{"key":"BFnrclinonc2017197_CR36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","volume":"17","author":"AS Sperling","year":"2017","unstructured":"Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5\u201319 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc2017197_CR37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2741\/3913","volume":"17","author":"D Park","year":"2012","unstructured":"Park, D., Sykes, D. B. & Scadden, D. T. The hematopoietic stem cell niche. Front. Biosci. 17, 30\u201339 (2012).","journal-title":"Front. Biosci."},{"key":"BFnrclinonc2017197_CR38","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2007-08-078147","volume":"111","author":"T Papayannopoulou","year":"2008","unstructured":"Papayannopoulou, T. & Scadden, D. T. Stem-cell ecology and stem cells in motion. Blood 111, 3923\u20133930 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.ctdb.2016.01.009","volume":"118","author":"VW Yu","year":"2016","unstructured":"Yu, V. W. & Scadden, D. T. Hematopoietic stem cell and its bone marrow niche. Curr. Top. Dev. Biol. 118, 21\u201344 (2016).","journal-title":"Curr. Top. Dev. Biol."},{"key":"BFnrclinonc2017197_CR40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820\u2013827 (2005).","journal-title":"Nature"},{"key":"BFnrclinonc2017197_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275\u2013292 (2011).","journal-title":"Cell"},{"key":"BFnrclinonc2017197_CR42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"BFnrclinonc2017197_CR43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.1090922","volume":"303","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848\u2013851 (2004).","journal-title":"Science"},{"key":"BFnrclinonc2017197_CR44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2007.03.055","volume":"129","author":"CR Walkley","year":"2007","unstructured":"Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E. & Orkin, S. H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129, 1081\u20131095 (2007).","journal-title":"Cell"},{"key":"BFnrclinonc2017197_CR45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"FC Yang","year":"2008","unstructured":"Yang, F. C. et al. Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2212 and c-kit-dependent bone marrow. Cell 135, 437\u2013448 (2008).","journal-title":"Cell"},{"key":"BFnrclinonc2017197_CR46","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852\u2013857 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc2017197_CR47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature12883","volume":"506","author":"A Kode","year":"2014","unstructured":"Kode, A. et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 506, 240\u2013244 (2014).","journal-title":"Nature"},{"key":"BFnrclinonc2017197_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2015.161","volume":"30","author":"A Kode","year":"2016","unstructured":"Kode, A. et al. FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice. Leukemia 30, 1\u201313 (2016).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR49","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1359\/jbmr.2002.17.11.1921","volume":"17","author":"GD Roodman","year":"2002","unstructured":"Roodman, G. D. Role of the bone marrow microenvironment in multiple myeloma. J. Bone Miner. Res. 17, 1921\u20131925 (2002).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrclinonc2017197_CR50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.beha.2007.08.002","volume":"20","author":"K Podar","year":"2007","unstructured":"Podar, K., Richardson, P. G., Hideshima, T., Chauhan, D. & Anderson, K. C. The malignant clone and the bone-marrow environment. Best Pract. Res. Clin. Haematol. 20, 597\u2013612 (2007).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"BFnrclinonc2017197_CR51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1517\/14728222.9.2.359","volume":"9","author":"K Podar","year":"2005","unstructured":"Podar, K., Hideshima, T., Chauhan, D. & Anderson, K. C. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin. Ther. Targets 9, 359\u2013381 (2005).","journal-title":"Expert Opin. Ther. Targets"},{"key":"BFnrclinonc2017197_CR52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar, K., Chauhan, D. & Anderson, K. C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23, 10\u201324 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","volume":"18","author":"MR Reagan","year":"2012","unstructured":"Reagan, M. R. & Ghobrial, I. M. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer Res. 18, 342\u2013349 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2017197_CR54","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","volume":"129","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood 129, 2429\u20132436 (2017).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR55","first-page":"16","volume":"1","author":"J Wang","year":"2014","unstructured":"Wang, J. & Xiao, Z. Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes. Stem Cell. Investig. 1, 16 (2014).","journal-title":"Stem Cell. Investig."},{"key":"BFnrclinonc2017197_CR56","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.yexcr.2011.08.007","volume":"317","author":"CM Aanei","year":"2011","unstructured":"Aanei, C. M. et al. Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Exp. Cell Res. 317, 2616\u20132629 (2011).","journal-title":"Exp. Cell Res."},{"key":"BFnrclinonc2017197_CR57","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1089\/scd.2011.0390","volume":"21","author":"CM Aanei","year":"2012","unstructured":"Aanei, C. M. et al. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev. 21, 1604\u20131615 (2012).","journal-title":"Stem Cells Dev."},{"key":"BFnrclinonc2017197_CR58","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2013.193","volume":"27","author":"S Geyh","year":"2013","unstructured":"Geyh, S. et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27, 1841\u20131851 (2013).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR59","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1182\/blood-2011-03-343467","volume":"118","author":"O Blau","year":"2011","unstructured":"Blau, O. et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 118, 5583\u20135592 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.exphem.2006.10.012","volume":"35","author":"O Blau","year":"2007","unstructured":"Blau, O. et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp. Hematol. 35, 221\u2013229 (2007).","journal-title":"Exp. Hematol."},{"key":"BFnrclinonc2017197_CR61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.exphem.2012.10.009","volume":"41","author":"FM Oliveira","year":"2013","unstructured":"Oliveira, F. M. et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Exp. Hematol. 41, 198\u2013208 (2013).","journal-title":"Exp. Hematol."},{"key":"BFnrclinonc2017197_CR62","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.leukres.2003.11.019","volume":"28","author":"R Borojevic","year":"2004","unstructured":"Borojevic, R. et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk. Res 28, 831\u2013844 (2004).","journal-title":"Leuk. Res"},{"key":"BFnrclinonc2017197_CR63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exphem.2013.10.002","volume":"42","author":"X Li","year":"2014","unstructured":"Li, X. & Deeg, H. J. Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp. Hematol. 42, 4\u201310 (2014).","journal-title":"Exp. Hematol."},{"key":"BFnrclinonc2017197_CR64","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","volume":"14","author":"H Medyouf","year":"2014","unstructured":"Medyouf, H. et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14, 824\u2013837 (2014).","journal-title":"Cell Stem Cell"},{"key":"BFnrclinonc2017197_CR65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.exphem.2009.11.009","volume":"38","author":"K Todoerti","year":"2010","unstructured":"Todoerti, K. et al. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp. Hematol. 38, 141\u2013153 (2010).","journal-title":"Exp. Hematol."},{"key":"BFnrclinonc2017197_CR66","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/leu.2009.65","volume":"23","author":"M Garayoa","year":"2009","unstructured":"Garayoa, M. et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23, 1515\u20131527 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.leukres.2004.06.011","volume":"29","author":"E Flores-Figueroa","year":"2005","unstructured":"Flores-Figueroa, E., Arana-Trejo, R. M., Guti\u00e9rrez-Esp\u00edndola, G., P\u00e9rez-Cabrera, A. & Mayani, H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk. Res. 29, 215\u2013224 (2005).","journal-title":"Leuk. Res."},{"key":"BFnrclinonc2017197_CR68","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3324\/haematol.2011.054437","volume":"97","author":"C Santamaria","year":"2012","unstructured":"Santamaria, C. et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 97, 1218\u20131224 (2012).","journal-title":"Haematologica"},{"key":"BFnrclinonc2017197_CR69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","volume":"19","author":"NA Zambetti","year":"2016","unstructured":"Zambetti, N. A. et al. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 19, 613\u2013627 (2016).","journal-title":"Cell Stem Cell"},{"key":"BFnrclinonc2017197_CR70","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-13-2645","volume":"74","author":"SW Olechnowicz","year":"2014","unstructured":"Olechnowicz, S. W. & Edwards, C. M. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res. 74, 1625\u20131631 (2014).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2017197_CR71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.14310\/horm.2002.1111024","volume":"6","author":"MP Yavropoulou","year":"2007","unstructured":"Yavropoulou, M. P. & Yovos, J. G. The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones 6, 279\u2013294 (2007).","journal-title":"Hormones"},{"key":"BFnrclinonc2017197_CR72","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman, G. D. Pathogenesis of myeloma bone disease. Leukemia 23, 435\u2013441 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR73","doi-asserted-by":"crossref","first-page":"6270s","DOI":"10.1158\/1078-0432.CCR-06-0845","volume":"12","author":"GD Roodman","year":"2006","unstructured":"Roodman, G. D. New potential targets for treating myeloma bone disease. Clin. Cancer Res. 12, 6270s\u20136273s (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2017197_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12578","volume":"1335","author":"D Toscani","year":"2015","unstructured":"Toscani, D., Bolzoni, M., Accardi, F., Aversa, F. & Giuliani, N. The osteoblastic niche in the context of multiple myeloma. Ann. NY Acad. Sci. 1335, 45\u201362 (2015).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrclinonc2017197_CR75","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi, G. & Munshi, N. C. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125, 3049\u20133058 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/14796694.2.3.371","volume":"2","author":"A Huston","year":"2006","unstructured":"Huston, A. & Roodman, G. D. Role of the microenvironment in multiple myeloma bone disease. Future Oncol. 2, 371\u2013378 (2006).","journal-title":"Future Oncol."},{"key":"BFnrclinonc2017197_CR77","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2011-12-398537","volume":"120","author":"C Tripodo","year":"2012","unstructured":"Tripodo, C. et al. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 120, 3541\u20133554 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR78","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2015-06-653113","volume":"127","author":"SR Balderman","year":"2016","unstructured":"Balderman, S. R. et al. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome. Blood 127, 616\u2013625 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR79","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/sj.leu.2400844","volume":"11","author":"M Kitagawa","year":"1997","unstructured":"Kitagawa, M. et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11, 2049\u20132054 (1997).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR80","doi-asserted-by":"crossref","first-page":"e57470","DOI":"10.1371\/journal.pone.0057470","volume":"8","author":"Z Wang","year":"2013","unstructured":"Wang, Z. et al. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PLoS ONE 8, e57470 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc2017197_CR81","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02982044","volume":"75","author":"K Allampallam","year":"2002","unstructured":"Allampallam, K. et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte\/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int. J. Hematol. 75, 289\u2013297 (2002).","journal-title":"Int. J. Hematol."},{"key":"BFnrclinonc2017197_CR82","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3324\/haematol.2010.030536","volume":"96","author":"X Feng","year":"2011","unstructured":"Feng, X. et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 96, 602\u2013606 (2011).","journal-title":"Haematologica"},{"key":"BFnrclinonc2017197_CR83","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss, G. & Goodnough, L. T. Anemia of chronic disease. N. Engl. J. Med. 352, 1011\u20131023 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR84","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1182\/blood.V99.11.4138","volume":"99","author":"YW Qiang","year":"2002","unstructured":"Qiang, Y. W., Kopantzev, E. & Rudikoff, S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99, 4138\u20134146 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR85","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","volume":"109","author":"Y Alsayed","year":"2007","unstructured":"Alsayed, Y. et al. Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109, 2708\u20132717 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR86","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","volume":"95","author":"B Dankbar","year":"2000","unstructured":"Dankbar, B. et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95, 2630\u20132636 (2000).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR87","doi-asserted-by":"crossref","first-page":"27845","DOI":"10.1074\/jbc.M003428200","volume":"275","author":"D Chauhan","year":"2000","unstructured":"Chauhan, D. et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem. 275, 27845\u201327850 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrclinonc2017197_CR88","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2013-06-511527","volume":"123","author":"R Jacamo","year":"2014","unstructured":"Jacamo, R. et al. Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood 123, 2691\u20132702 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR89","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2017197_CR90","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137\u20131146 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc2017197_CR91","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jtos.2015.11.004","volume":"14","author":"VJ Coulson-Thomas","year":"2016","unstructured":"Coulson-Thomas, V. J., Coulson-Thomas, Y. M., Gesteira, T. F. & Kao, W. W. Extrinsic and intrinsic mechanisms by which mesenchymal stem cells suppress the immune system. Ocul. Surf. 14, 121\u2013134 (2016).","journal-title":"Ocul. Surf."},{"key":"BFnrclinonc2017197_CR92","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/nyas.12815","volume":"1351","author":"A Uccelli","year":"2015","unstructured":"Uccelli, A. & de Rosbo, N. K. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann. NY Acad. Sci. 1351, 114\u2013126 (2015).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrclinonc2017197_CR93","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4049\/jimmunol.0902007","volume":"185","author":"S Ghannam","year":"2010","unstructured":"Ghannam, S., Pene, J., Moquet-Torcy, G., Jorgensen, C. & Yssel, H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185, 302\u2013312 (2010).","journal-title":"J. Immunol."},{"key":"BFnrclinonc2017197_CR94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/scrt2","volume":"1","author":"S Ghannam","year":"2010","unstructured":"Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C. & Noel, D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res. Ther. 1, 2 (2010).","journal-title":"Stem Cell Res. Ther."},{"key":"BFnrclinonc2017197_CR95","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235\u2013238 (2006).","journal-title":"Nature"},{"key":"BFnrclinonc2017197_CR96","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","volume":"116","author":"K Noonan","year":"2010","unstructured":"Noonan, K. et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116, 3554\u20133563 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR97","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","volume":"144","author":"S Feyler","year":"2009","unstructured":"Feyler, S. et al. CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4\u2212CD8\u2212\u03b1\u03b2TCR+ double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 144, 686\u2013695 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR98","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"BFnrclinonc2017197_CR99","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","volume":"100","author":"N Giuliani","year":"2002","unstructured":"Giuliani, N. et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100, 4615\u20134621 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR100","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2009.130","volume":"23","author":"M Roussou","year":"2009","unstructured":"Roussou, M. et al. Increased expression of macrophage inflammatory protein-1\u03b1 on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 23, 2177\u20132181 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR101","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","volume":"121","author":"GT Gorgun","year":"2013","unstructured":"Gorgun, G. T. et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121, 2975\u20132987 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR102","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrclinonc2017197_CR103","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1182\/blood.V126.23.502.502","volume":"126","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Characterization of the role of regulatory T cells (Tregs) in inducing progression of multiple myeloma. Blood 126, 502 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2016.00151","volume":"6","author":"DA Sallman","year":"2016","unstructured":"Sallman, D. A., Cluzeau, T., Basiorka, A. A. & List, A. Unraveling the pathogenesis of MDS: the NLRP3 inflammasome and pyroptosis drive the MDS phenotype. Front. Oncol. 6, 151 (2016).","journal-title":"Front. Oncol."},{"key":"BFnrclinonc2017197_CR105","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","volume":"128","author":"AA Basiorka","year":"2016","unstructured":"Basiorka, A. A. et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128, 2960\u20132975 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR106","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.2016.151514","volume":"102","author":"J Xin","year":"2017","unstructured":"Xin, J. et al. Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in mice. Haematologica 102, 295\u2013307 (2017).","journal-title":"Haematologica"},{"key":"BFnrclinonc2017197_CR107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"BFnrclinonc2017197_CR108","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.exphem.2016.04.012","volume":"44","author":"U Testa","year":"2016","unstructured":"Testa, U., Labbaye, C., Castelli, G. & Pelosi, E. Oxidative stress and hypoxia in normal and leukemic stem cells. Exp. Hematol. 44, 540\u2013560 (2016).","journal-title":"Exp. Hematol."},{"key":"BFnrclinonc2017197_CR109","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1074\/jbc.M115.688762","volume":"291","author":"T Laukka","year":"2016","unstructured":"Laukka, T. et al. Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. J. Biol. Chem. 291, 4256\u20134265 (2016).","journal-title":"J. Biol. Chem."},{"key":"BFnrclinonc2017197_CR110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","volume":"32","author":"D Passaro","year":"2017","unstructured":"Passaro, D. et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell 32, 324\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2017197_CR111","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.neo.2015.04.001","volume":"17","author":"L Teofili","year":"2015","unstructured":"Teofili, L. et al. Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia. Neoplasia 17, 401\u2013409 (2015).","journal-title":"Neoplasia"},{"key":"BFnrclinonc2017197_CR112","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/leu.2010.193","volume":"24","author":"S Colla","year":"2010","unstructured":"Colla, S. et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1\u03b1 overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia 24, 1967\u20131970 (2010).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR113","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab, A. K. et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119, 5782\u20135794 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR114","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/leu.2017.102","volume":"31","author":"SV Glavey","year":"2017","unstructured":"Glavey, S. V. et al. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia 31, 2426\u20132434 (2017).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V100.2.610","volume":"100","author":"Y Yang","year":"2002","unstructured":"Yang, Y. et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610\u2013617 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR116","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12920-017-0253-6","volume":"10","author":"A Foroushani","year":"2017","unstructured":"Foroushani, A. et al. Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. BMC Med. Genom. 10, 16 (2017).","journal-title":"BMC Med. Genom."},{"key":"BFnrclinonc2017197_CR117","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR118","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03204.x","volume":"115","author":"F Zorat","year":"2001","unstructured":"Zorat, F. et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. 115, 881\u2013894 (2001).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR119","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/1042819021000029777","volume":"44","author":"A Aguayo","year":"2003","unstructured":"Aguayo, A., Giles, F. & Albitar, M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk. Lymphoma 44, 213\u2013222 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2017197_CR120","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.pmed.0050035","volume":"5","author":"BL Ebert","year":"2008","unstructured":"Ebert, B. L. et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 5, e35 (2008).","journal-title":"PLoS Med."},{"key":"BFnrclinonc2017197_CR121","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","volume":"77","author":"L Lu","year":"2009","unstructured":"Lu, L. et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res. 77, 78\u201386 (2009).","journal-title":"Microvasc. Res."},{"key":"BFnrclinonc2017197_CR122","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"BFnrclinonc2017197_CR123","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"BFnrclinonc2017197_CR124","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3109\/10428194.2013.778406","volume":"54","author":"EN Oliva","year":"2013","unstructured":"Oliva, E. N. et al. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk. Lymphoma 54, 2458\u20132465 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2017197_CR125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1756-8722-5-71","volume":"5","author":"ES Wang","year":"2012","unstructured":"Wang, E. S. et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J. Hematol. Oncol. 5, 71 (2012).","journal-title":"J. Hematol. Oncol."},{"key":"BFnrclinonc2017197_CR126","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","volume":"111","author":"A Swami","year":"2014","unstructured":"Swami, A. et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc. Natl Acad. Sci. USA 111, 10287\u201310292 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc2017197_CR127","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0093-7754(01)90024-7","volume":"28","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar, S. V. & Kyle, R. A. Angiogenesis in multiple myeloma. Semin. Oncol. 28, 560\u2013564 (2001).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc2017197_CR128","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR129","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR131","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR132","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR133","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355\u20131363 (2013).","journal-title":"Cancer Discov."},{"key":"BFnrclinonc2017197_CR134","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson, D. M. Jr et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286\u20132294 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","volume":"34","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt, J. et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine. J. Immunother. 34, 409\u2013418 (2011).","journal-title":"J. Immunother."},{"key":"BFnrclinonc2017197_CR136","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/leu.2013.310","volume":"28","author":"D Atanackovic","year":"2014","unstructured":"Atanackovic, D., Luetkens, T. & Kroger, N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 28, 993\u20131000 (2014).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR137","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","volume":"130","author":"A Badros","year":"2017","unstructured":"Badros, A. et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Blood 130, 1189\u20131197 (2017).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR138","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.critrevonc.2015.06.006","volume":"96","author":"AO Ayed","year":"2015","unstructured":"Ayed, A. O., Chang, L. J. & Moreb, J. S. Immunotherapy for multiple myeloma: current status and future directions. Crit. Rev. Oncol. Hematol. 96, 399\u2013412 (2015).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"BFnrclinonc2017197_CR139","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/CCO.0000000000000212","volume":"27","author":"CY Cheah","year":"2015","unstructured":"Cheah, C. Y., Fowler, N. H. & Neelapu, S. S. Targeting the programmed death-1\/programmed death-ligand 1 axis in lymphoma. Curr. Opin. Oncol. 27, 384\u2013391 (2015).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrclinonc2017197_CR140","doi-asserted-by":"crossref","first-page":"e1254856","DOI":"10.1080\/2162402X.2016.1254856","volume":"5","author":"T Jelinek","year":"2016","unstructured":"Jelinek, T. & Hajek, R. PD-1\/PD-L1 inhibitors in multiple myeloma: the present and the future. Oncoimmunology 5, e1254856 (2016).","journal-title":"Oncoimmunology"},{"key":"BFnrclinonc2017197_CR141","unstructured":"[No authors listed] FDA alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating KEYTRUDA\u00ae (pembrolizumab) in patients with multiple myeloma. US Food and Drug Administration https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm574305.htm (2017)."},{"key":"BFnrclinonc2017197_CR142","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3332\/ecancer.2015.514","volume":"9","author":"A Agazzi","year":"2015","unstructured":"Agazzi, A. Report on the 56th ASH Annual Meeting, San Francisco, 4\u20139 December 2014. ecancermedicalscience 9, 514 (2015).","journal-title":"ecancermedicalscience"},{"key":"BFnrclinonc2017197_CR143","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","volume":"172","author":"D Atanackovic","year":"2016","unstructured":"Atanackovic, D., Radhakrishnan, S. V., Bhardwaj, N. & Luetkens, T. Chimeric antigen receptor (CAR) therapy for multiple myeloma. Br. J. Haematol. 172, 685\u2013698 (2016).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR144","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/labinvest.2014.110","volume":"94","author":"S Abe-Suzuki","year":"2014","unstructured":"Abe-Suzuki, S. et al. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Lab. Invest. 94, 1212\u20131223 (2014).","journal-title":"Lab. Invest."},{"key":"BFnrclinonc2017197_CR145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.leukres.2011.06.017","volume":"36","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. SDF-1\/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. Leuk. Res. 36, 281\u2013286 (2012).","journal-title":"Leuk. Res."},{"key":"BFnrclinonc2017197_CR146","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","volume":"11","author":"EA Sison","year":"2013","unstructured":"Sison, E. A., McIntyre, E., Magoon, D. & Brown, P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol. Cancer Res. 11, 1004\u20131016 (2013).","journal-title":"Mol. Cancer Res."},{"key":"BFnrclinonc2017197_CR147","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2017.5","volume":"31","author":"H Ludwig","year":"2017","unstructured":"Ludwig, H. et al. Olaptesed pegol, an anti-CXCL12\/SDF-1 Spiegelmer, alone and with bortezomib dexamethasone in relapsed\/refractory multiple myeloma: a phase IIa study. Leukemia 31, 997\u20131000 (2017).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR148","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","volume":"119","author":"GL Uy","year":"2012","unstructured":"Uy, G. L. et al. A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 119, 3917\u20133924 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR149","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","volume":"12","author":"GJ Morgan","year":"2011","unstructured":"Morgan, G. J. et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 12, 743\u2013752 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc2017197_CR150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","volume":"52","author":"G D'Arena","year":"2011","unstructured":"D'Arena, G. et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk. Lymphoma 52, 771\u2013775 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2017197_CR151","first-page":"215","volume":"30","author":"M Dong","year":"2008","unstructured":"Dong, M. et al. Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma [Chinese]. Zhonghua Zhong Liu Za Zhi 30, 215\u2013220 (2008).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"BFnrclinonc2017197_CR152","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98, 1735\u20131744 (2003).","journal-title":"Cancer"},{"key":"BFnrclinonc2017197_CR153","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","volume":"44","author":"P Musto","year":"2003","unstructured":"Musto, P. et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk. Lymphoma 44, 1545\u20131548 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2017197_CR154","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer, S. P. et al. A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br. J. Haematol. 167, 366\u2013375 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR155","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","volume":"110","author":"J Qian","year":"2007","unstructured":"Qian, J. et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110, 1587\u20131594 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR156","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","volume":"84","author":"R Vij","year":"2009","unstructured":"Vij, R. et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am. J. Hematol. 84, 650\u2013656 (2009).","journal-title":"Am. J. Hematol."},{"key":"BFnrclinonc2017197_CR157","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood-2014-08-551549","volume":"124","author":"IM Ghobrial","year":"2014","unstructured":"Ghobrial, I. M. & Landgren, O. How I treat smoldering multiple myeloma. Blood 124, 3380\u20133388 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR158","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1365-2141.2002.03279.x","volume":"116","author":"R Stasi","year":"2002","unstructured":"Stasi, R. & Amadori, S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br. J. Haematol. 116, 334\u2013337 (2002).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR159","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2010.08145.x","volume":"149","author":"BL Scott","year":"2010","unstructured":"Scott, B. L. et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br. J. Haematol. 149, 706\u2013710 (2010).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR160","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1365-2141.2009.08061.x","volume":"148","author":"BL Scott","year":"2010","unstructured":"Scott, B. L. et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br. J. Haematol. 148, 944\u2013947 (2010).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR161","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1002\/ajh.23780","volume":"89","author":"G Garcia-Manero","year":"2014","unstructured":"Garcia-Manero, G. et al. A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. Am. J. Hematol. 89, E156\u2013E162 (2014).","journal-title":"Am. J. Hematol."},{"key":"BFnrclinonc2017197_CR162","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/10428194.2015.1102245","volume":"57","author":"V Magarotto","year":"2016","unstructured":"Magarotto, V., Salvini, M., Bonello, F., Bringhen, S. & Palumbo, A. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins. Leuk. Lymphoma 57, 537\u2013556 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc2017197_CR163","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","volume":"90","author":"RZ Orlowski","year":"2015","unstructured":"Orlowski, R. Z. et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am. J. Hematol. 90, 42\u201349 (2015).","journal-title":"Am. J. Hematol."},{"key":"BFnrclinonc2017197_CR164","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1038\/bcj.2016.4","volume":"6","author":"JJ Shah","year":"2016","unstructured":"Shah, J. J. et al. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 6, e396 (2016).","journal-title":"Blood Cancer J."},{"key":"BFnrclinonc2017197_CR165","doi-asserted-by":"crossref","first-page":"30408","DOI":"10.18632\/oncotarget.4655","volume":"6","author":"F van Rhee","year":"2015","unstructured":"van Rhee, F. et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 6, 30408\u201330419 (2015).","journal-title":"Oncotarget"},{"key":"BFnrclinonc2017197_CR166","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","volume":"165","author":"S Carrancio","year":"2014","unstructured":"Carrancio, S. et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br. J. Haematol. 165, 870\u2013882 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR167","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V126.23.92.92","volume":"126","author":"A Giagounidis","year":"2015","unstructured":"Giagounidis, A. et al. Luspatercept treatment leads to long term increases in hemoglobin and reductions in transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from the phase 2 PACE-MDS extension study. Blood 126, 92 (2015).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR168","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nm.3468","volume":"20","author":"M Dussiot","year":"2014","unstructured":"Dussiot, M. et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat. Med. 20, 398\u2013407 (2014).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2017197_CR169","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2017.06.004","volume":"54","author":"A Mies","year":"2017","unstructured":"Mies, A. & Platzbecker, U. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-beta superfamily inhibitors. Semin. Hematol. 54, 141\u2013146 (2017).","journal-title":"Semin. Hematol."},{"key":"BFnrclinonc2017197_CR170","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.2112","volume":"16","author":"DW McMillin","year":"2010","unstructured":"McMillin, D. W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483\u2013489 (2010).","journal-title":"Nat. Med."},{"key":"BFnrclinonc2017197_CR171","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500\u2013504 (2012).","journal-title":"Nature"},{"key":"BFnrclinonc2017197_CR172","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","volume":"116","author":"S Yaccoby","year":"2002","unstructured":"Yaccoby, S. et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 116, 278\u2013290 (2002).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR173","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","volume":"124","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 124, 555\u2013566 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR174","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28, 155\u2013165 (2014).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR175","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood.V118.21.625.625","volume":"118","author":"M Roccaro","year":"2011","unstructured":"Roccaro, M. et al. Stroma-derived exosomes mediate oncogenesis in multiple myeloma Blood 118, 625 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR176","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","volume":"75","author":"P Maiso","year":"2015","unstructured":"Maiso, P. et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 75, 2071\u20132082 (2015).","journal-title":"Cancer Res."},{"key":"BFnrclinonc2017197_CR177","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","volume":"116","author":"J Hu","year":"2010","unstructured":"Hu, J. et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116, 1524\u20131527 (2010).","journal-title":"Blood"},{"issue":"Suppl.","key":"BFnrclinonc2017197_CR178","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1200\/jco.2014.32.15_suppl.8534","volume":"32","author":"J Laubach","year":"2014","unstructured":"Laubach, J. et al. Preliminary safety and efficacy of TH-302, an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma (RR MM) [abstract]. J. Clin. Oncol. 32 (Suppl.), 8534 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR179","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2016.10.003","volume":"30","author":"J Bajaj","year":"2016","unstructured":"Bajaj, J. et al. CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. Cancer Cell 30, 792\u2013805 (2016).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2017197_CR180","doi-asserted-by":"crossref","first-page":"20054","DOI":"10.18632\/oncotarget.7911","volume":"7","author":"BZ Carter","year":"2016","unstructured":"Carter, B. Z. et al. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF\u03baB\/IL1\u03b2 signaling network. Oncotarget 7, 20054\u201320067 (2016).","journal-title":"Oncotarget"},{"key":"BFnrclinonc2017197_CR181","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454\u2013464 (2017).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR182","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","volume":"31","author":"G Ghiaur","year":"2017","unstructured":"Ghiaur, G. & Levis, M. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. Hematol. Oncol. Clin. North Am. 31, 681\u2013692 (2017).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"BFnrclinonc2017197_CR183","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2002.03551.x","volume":"118","author":"S Verstovsek","year":"2002","unstructured":"Verstovsek, S. et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br. J. Haematol. 118, 151\u2013156 (2002).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR184","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/cncr.20187","volume":"100","author":"Q Hu","year":"2004","unstructured":"Hu, Q. et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 100, 1884\u20131891 (2004).","journal-title":"Cancer"},{"key":"BFnrclinonc2017197_CR185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2003.04.182","volume":"21","author":"E Verburgh","year":"2003","unstructured":"Verburgh, E. et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J. Clin. Oncol. 21, 273\u2013282 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR186","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/blood-2016-08-736454","volume":"129","author":"A Stoddart","year":"2017","unstructured":"Stoddart, A. et al. Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel\/+ MDS mouse model. Blood 129, 2959\u20132970 (2017).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR187","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","volume":"129","author":"A Shastri","year":"2017","unstructured":"Shastri, A., Will, B., Steidl, U. & Verma, A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood 129, 1586\u20131594 (2017).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR188","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","volume":"123","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J. Clin. Invest. 123, 4595\u20134611 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc2017197_CR189","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","volume":"16","author":"D Chauhan","year":"2009","unstructured":"Chauhan, D. et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 16, 309\u2013323 (2009).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc2017197_CR190","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1038\/leu.2017.135","volume":"31","author":"A Ray","year":"2017","unstructured":"Ray, A. et al. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. Leukemia 31, 2652\u20132660 (2017).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR191","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2011.08872.x","volume":"156","author":"SM Vercauteren","year":"2012","unstructured":"Vercauteren, S. M. et al. T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone. Br. J. Haematol. 156, 409\u2013412 (2012).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc2017197_CR192","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2404590","volume":"21","author":"PK Epling-Burnette","year":"2007","unstructured":"Epling-Burnette, P. K. et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 21, 659\u2013667 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc2017197_CR193","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565\u20131571 (1999).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrclinonc2017197_CR194","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/jco.2006.24.18_suppl.7521","volume":"24","author":"D Weber","year":"2006","unstructured":"Weber, D. et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]. J. Clin. Oncol. 24, (Suppl.), 7521 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR195","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos, M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123\u20132132 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR196","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial, S. et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953\u20131959 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR197","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.V124.21.291.291","volume":"124","author":"AA Lesokhin","year":"2014","unstructured":"Lesokhin, A. A. et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 124, 291 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc2017197_CR198","first-page":"393","volume":"14","author":"P Sidaway","year":"2017","unstructured":"Sidaway, P. Haematological cancer: Pembrolizumab is effective in multiple myeloma. Nat. Rev. Clin. Oncol. 14, 393 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc2017197_CR199","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143\u2013153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2017197_CR200","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","volume":"7","author":"KA Noonan","year":"2015","unstructured":"Noonan, K. A. et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci. Transl Med. 7, 288ra78 (2015).","journal-title":"Sci. Transl Med."},{"key":"BFnrclinonc2017197_CR201","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4161\/21645515.2014.982993","volume":"10","author":"AR Pyzer","year":"2014","unstructured":"Pyzer, A. R., Avigan, D. E. & Rosenblatt, J. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum. Vaccin. Immunother. 10, 3125\u20133131 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"BFnrclinonc2017197_CR202","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","volume":"19","author":"J Rosenblatt","year":"2013","unstructured":"Rosenblatt, J. et al. Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19, 3640\u20133648 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc2017197_CR203","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood.V118.21.1874.1874","volume":"118","author":"I Ghobrial","year":"2011","unstructured":"Ghobrial, I. et al. Phase I trial of plerixafor and bortezomib as a chemosensitization strategy in relapsed or relapsed\/refractory multiple myeloma. Blood 118, 1874 (2011).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2017.197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2017.197","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrclinonc.2017.197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2017.197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:32:44Z","timestamp":1684467164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2017.197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":203,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFnrclinonc2017197"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2017.197","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]},"assertion":[{"value":"9 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}